Targeting cancer with
Power+Precision tm

Welcome to Viventia Bio Inc.

Broad, Clinical-Stage Oncology Pipeline

Viventia is advancing a broad pipeline of Targeted Protein Therapeutics (TPTs), which are fully biologic fusion constructs containing antibody fragments, “Precision,” combined using a proprietary linker with protein toxin payloads “Power.”

Two Programs Entering Phase III

Viventia’s late stage pipeline includes Vicinium for non-muscle invasive bladder cancer and Proxinium for squamous cell carcinoma of the head and neck.

Robust Platform

Viventia has additional early stage products using its TPT technology platform that we expect to re-enter the clinic in phase II shortly.